|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.68 USD | -8.77% |
|
-6.06% | +17.89% |
| 07-08 | Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise | MT |
| 07-08 | Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration | MT |
Business description: Beam Therapeutics Inc.
Number of employees: 522
Sales by Activity: Beam Therapeutics Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology (Startups) | 51.84M | 60.92M | 378M | 63.52M | 140M |
Geographical breakdown of sales: Beam Therapeutics Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 51.84M | 60.92M | 378M | 63.52M | 140M |
Executive Committee: Beam Therapeutics Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
John Evans
CEO | Chief Executive Officer | 48 | 31/12/2016 |
Sravan Emany
DFI | Director of Finance/CFO | 48 | 18/12/2024 |
| President | 57 | 23/01/2020 | |
Gopi Shanker
CTO | Chief Tech/Sci/R&D Officer | - | 20/03/2023 |
Amy Simon
CTO | Chief Tech/Sci/R&D Officer | 62 | 14/03/2021 |
Composition of the Board of Directors: Beam Therapeutics Inc.
| Director | Title | Age | Since |
|---|---|---|---|
John Evans
BRD | Director/Board Member | 48 | 31/12/2016 |
Mark Fishman
BRD | Director/Board Member | 75 | 30/04/2018 |
Graham Cooper
BRD | Director/Board Member | 56 | 09/10/2019 |
Kathleen Walsh
BRD | Director/Board Member | 70 | 09/01/2021 |
John Maraganore
BRD | Director/Board Member | 62 | 04/11/2021 |
Christi Shaw
BRD | Director/Board Member | 59 | 13/12/2023 |
Chirfi Guindo
BRD | Director/Board Member | 60 | 01/12/2024 |
Company details: Beam Therapeutics Inc.
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.77% | -6.06% | +54.44% | +2.25% | 3.25B | |
| +0.58% | +2.06% | +3.90% | +10.40% | 50.73B | |
| -2.22% | -1.25% | +391.53% | +591.38% | 39.73B | |
| -0.54% | +0.39% | +27.67% | -3.89% | 34.69B | |
| -1.36% | +0.35% | +19.34% | +58.83% | 33.21B | |
| +1.21% | -4.58% | +3.00% | +37.03% | 26.76B | |
| -1.81% | -1.48% | - | - | 16.8B | |
| +0.51% | -3.47% | +66.38% | +125.61% | 15.37B | |
| +0.23% | -0.58% | +13.80% | +19.56% | 13.78B | |
| -0.62% | -3.09% | +11.43% | -29.93% | 12.85B | |
| Average | -1.28% | -1.35% | +65.72% | +90.14% | 24.72B | |
| Weighted average by Cap. | -0.59% | -0.31% | +82.35% | +124.39% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BEAM Stock
- Company Beam Therapeutics Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition